TBPH240621P10000
- 1.25
- 0.000.00%
Theravance Biopharma Newsroom
Investors in Theravance Biopharma (NASDAQ:TBPH) Have Unfortunately Lost 52% Over the Last Five Years
Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday.Shares of Mama's Creations Inc (NASDAQ:MAMA) fell in today's pre-market trading following fi
Sidoti Events, LLC's Virtual June Small-Cap Conference
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Conference tak
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Theravance Biopharma (TBPH) and Merus (MRUS)
TD Cowen Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Maintains Target Price $10
TD Cowen analyst Marc Frahm maintains $Theravance Biopharma(TBPH.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 47.0% and
Theravance Biopharma (TBPH) Receives a Hold From TD Cowen
BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $21
BTIG analyst Julian Harrison maintains $Theravance Biopharma(TBPH.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of 49.4% and
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Theravance Biopharma (TBPH)
Buy Rating Affirmed on Theravance Biopharma Amid Strong Q1 Performance and Promising Pipeline Prospects
Theravance Biopharma | 10-Q: Quarterly report
HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $20 price target.
Earnings Call Summary | Theravance Biopharma(TBPH.US) Q1 2024 Earnings Conference
The following is a summary of the Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript:Financial Performance:Theravance Biopharma reported Q1 net sales of $55.2 million in partnership wi
Buy Rating Affirmed for Theravance Biopharma on Strong Portfolio Performance and Promising Drug Prospects
Analysts Have Conflicting Sentiments on These Healthcare Companies: Theravance Biopharma (TBPH), Voyager Therapeutics (VYGR) and Praxis Precision Medicines (PRAX)
Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours
Theravance Biopharma (TBPH) Monday night reported a Q1 net loss of $0.24 per share, compared with $0.35 loss a year ago. Analysts polled by Capital IQ expected $0.25 loss. Revenue for the quarter ende
Theravance Biopharma Q1 2024 GAAP EPS $(0.24) Beats $(0.25) Estimate, Sales $14.503M Beat $13.963M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. The company reported quarterly sales of $14.503 mi
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q1 Revenue $14.5M, Vs. Street Est of $14M
04:10 PM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q1 Revenue $14.5M, vs. Street Est of $14M
Press Release: Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire DUBLIN, May 13, 2024 -- Q1 2024 YUPELRI(R) (revefenacin) net sales of $55.2 milli
Theravance Biopharma 1Q Loss/Shr 24c >TBPH
Theravance Biopharma 1Q Loss/Shr 24c >TBPH
Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at...